These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
571 related articles for article (PubMed ID: 28526920)
1. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Kapitza C; Dahl K; Jacobsen JB; Axelsen MB; Flint A Diabetologia; 2017 Aug; 60(8):1390-1399. PubMed ID: 28526920 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial. Wang W; Bain SC; Bian F; Chen R; Gabery S; Huang S; Jensen TB; Luo B; Yuan G; Ning G; Diabetologia; 2024 Sep; 67(9):1783-1799. PubMed ID: 38985162 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial. Ji L; Agesen RM; Bain SC; Fu F; Gabery S; Geng J; Li Y; Lu Y; Luo B; Pang W; Tao Y; Diabetologia; 2024 Sep; 67(9):1800-1816. PubMed ID: 38985161 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Sorli C; Harashima SI; Tsoukas GM; Unger J; Karsbøl JD; Hansen T; Bain SC Lancet Diabetes Endocrinol; 2017 Apr; 5(4):251-260. PubMed ID: 28110911 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659 [TBL] [Abstract][Full Text] [Related]
6. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322 [TBL] [Abstract][Full Text] [Related]
7. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. McCrimmon RJ; Catarig AM; Frias JP; Lausvig NL; le Roux CW; Thielke D; Lingvay I Diabetologia; 2020 Mar; 63(3):473-485. PubMed ID: 31897524 [TBL] [Abstract][Full Text] [Related]
8. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ; Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lingvay I; Catarig AM; Frias JP; Kumar H; Lausvig NL; le Roux CW; Thielke D; Viljoen A; McCrimmon RJ Lancet Diabetes Endocrinol; 2019 Nov; 7(11):834-844. PubMed ID: 31540867 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112 [TBL] [Abstract][Full Text] [Related]
11. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C; Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Frías JP; Auerbach P; Bajaj HS; Fukushima Y; Lingvay I; Macura S; Søndergaard AL; Tankova TI; Tentolouris N; Buse JB Lancet Diabetes Endocrinol; 2021 Sep; 9(9):563-574. PubMed ID: 34293304 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. McGowan BM; Bruun JM; Capehorn M; Pedersen SD; Pietiläinen KH; Muniraju HAK; Quiroga M; Varbo A; Lau DCW; Lancet Diabetes Endocrinol; 2024 Sep; 12(9):631-642. PubMed ID: 39089293 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Frias JP; Deenadayalan S; Erichsen L; Knop FK; Lingvay I; Macura S; Mathieu C; Pedersen SD; Davies M Lancet; 2023 Aug; 402(10403):720-730. PubMed ID: 37364590 [TBL] [Abstract][Full Text] [Related]
16. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Davies M; Færch L; Jeppesen OK; Pakseresht A; Pedersen SD; Perreault L; Rosenstock J; Shimomura I; Viljoen A; Wadden TA; Lingvay I; Lancet; 2021 Mar; 397(10278):971-984. PubMed ID: 33667417 [TBL] [Abstract][Full Text] [Related]
17. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. Rodbard HW; Lingvay I; Reed J; de la Rosa R; Rose L; Sugimoto D; Araki E; Chu PL; Wijayasinghe N; Norwood P J Clin Endocrinol Metab; 2018 Jun; 103(6):2291-2301. PubMed ID: 29688502 [TBL] [Abstract][Full Text] [Related]
18. Dose-response effects on HbA Blüher M; Rosenstock J; Hoefler J; Manuel R; Hennige AM Diabetologia; 2024 Mar; 67(3):470-482. PubMed ID: 38095657 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]